Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 2
1995 pubmed

The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation.

Jiang. J J; Sharma. S D SD; Nakamura. S S; Lai. J Y JY; Fink. J L JL; Hruby. V J VJ; Hadley. M E ME

Key Findings

  • Melanotan‑I increased tyrosinase (melanin enzyme) activity in a few melanoma cell lines, especially when cells were crowded.
  • The peptide markedly reduced the number of melanoma cells, indicating a cytostatic (growth‑inhibiting) effect.
  • The growth‑inhibiting effect lingered for days after the peptide was taken away, and cells showed shape changes toward a more dendritic form.

Practical Outcomes

  • For biohackers, this study suggests melanotan‑I might have anti‑cancer properties in theory, but the evidence is limited to petri‑dish experiments. It doesn’t provide dosing, safety, or real‑world protocols, so it’s not a reliable basis for self‑administration aimed at health or performance benefits.

Summary

In lab tests, the synthetic peptide melanotan‑I (a strong melanin‑stimulating hormone) sometimes boosted the melanin‑making enzyme in melanoma cells and consistently slowed down their growth, even after the peptide was removed. However, these results are from cell cultures, not humans, so they don’t give clear guidance for personal use.

Abstract

Seventeen human melanoma cell (HMC) lines, both melanotic and amelanotic, were incubated in the continuous presence of a potent melanotropic peptide hormone analog, [Nle4,D-Phe7] alpha-MSH, for 72 hr with daily changes of medium. Only one cell line (HD, melanotic) consistently responded to the hormone analog by increased tyrosinase activity. Three (one melanotic, two amelanotic) of the HMC lines also failed to respond to the peptide by either increased or decreased enzyme activity when incubated continuously in the presence of the peptide for longer periods of time (6,15,27,43 days). The HD cell line, however, again responded with increasingly enhanced basal enzyme activity the longer the cells were incubated in the presence of the melanotropin. One amelanotic cell line (C8161) responded with enhanced enzyme activity when grown to confluency in the continuous presence of the peptide. Basal tyrosinase activity of the C8161 cell line may have increased as cell density in the flasks increased. These results suggest that under conditions of increased cell number, phenotypic expression of tyrosinase activity in so called "amelanotic" (tyrosinase-negative) cells is increased and can be enhanced further by stimulation with a melanotropic peptide. Under conditions of increased cell number, the presence of [Nle4,D-Phe7] alpha-MSH caused morphological differentiation (shape change); the cells became enlarged and very dendritic. The number of cells in monolayer (surface of the flask) and in the medium were drastically reduced in both melanotic and "amelanotic" cell lines incubated with [Nle4,D-Phe7] alpha-MSH. The data support other published reports that melanotropic peptides inhibit human melanoma cell growth (proliferation) in vitro, most likely through a cytostatic mechanism. [Nle4,D-Phe7] alpha-MSH also exhibited a prolonged (residual) inhibitory action on HD cell proliferation. In other words, inhibition of cell growth (proliferation) of the HMCs was evident even several days after removal of the melanotropic peptide from the incubation medium.

Study Information

Provider

pubmed

Year

1995

DOI

10.1111/j.1600-0749.1995.tb00680.x